Next Article in Journal
Standardized Outcomes Measures in Physical Therapy Practice for Treatment and Rehabilitation of Cerebral PALSY: A Systematic Review
Next Article in Special Issue
Salivary DNA Methylation as an Epigenetic Biomarker for Head and Neck Cancer. Part II: A Cancer Risk Meta-Analysis
Previous Article in Journal
Radiation Biomarkers: Silver Bullet, or Wild Goose Chase?
Previous Article in Special Issue
Detection of Aberrant Glycosylation of Serum Haptoglobin for Gastric Cancer Diagnosis Using a Middle-Up-Down Glycoproteome Platform
Article

Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer

1
Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, 0379 Oslo, Norway
2
Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway
3
Faculty of Clinical Medicine, University of Stettin, 70-111 Szczecin, Poland
4
Department of Radiotherapy, University of California, Los Angeles, CA 90095, USA
5
Department of Oncology, Østfold Hospital Trust, 1714 Kalnes, Norway
6
Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway
7
Department of Oncology, Oslo University Hospital, 0379 Oslo, Norway
*
Author to whom correspondence should be addressed.
Academic Editor: James Meehan
J. Pers. Med. 2021, 11(7), 605; https://doi.org/10.3390/jpm11070605
Received: 14 May 2021 / Revised: 21 June 2021 / Accepted: 22 June 2021 / Published: 26 June 2021
(This article belongs to the Special Issue Cancer Biomarker Research and Personalized Medicine)
De novo metastatic or recurrence of prostate cancer (PC) remains life-threatening. Circulating tumor cells (CTCs) are noninvasive biomarkers and provide unique information that could enable tailored treatment. This study evaluated the impact of CTCs in PC patients eligible for peptide vaccine therapy. Twenty-seven patients were tested for CTCs with the CellCollector® device (Detector CANCER01(DC01)) during short-term androgen deprivation therapy (ADT) before cancer vaccine treatment (cohort 1) or salvage radiation (cohort 2). CTC counts were compared to clinicopathological parameters. In cohort 1, CTCs were correlated to immune responses, serum protein profiles, and clinical outcomes. In cohort 2, captured CTCs were further profiled for expression of PSMA, PAP, and PD-L1. Nine out of 22 patients (40.9%) in cohort 1 were CTC positive. These patients demonstrated vaccine-specific immune response (p = 0.009) and long-term prostate cancer-specific survival (log-rank, p = 0.008). All five patients in cohort 2 had CTCs at recurrence (count range 18–31), and 4/5 had CTCs positive for PSMA, PAP, and PD-L1. The DC01 CTC detection provides information beyond current clinical practice. Despite the small size of cohort 1, a correlation between CTC detection and outcome was shown. View Full-Text
Keywords: circulating tumor cells; prostate cancer; cancer vaccine; immune response; biomarker circulating tumor cells; prostate cancer; cancer vaccine; immune response; biomarker
Show Figures

Graphical abstract

MDPI and ACS Style

Guldvik, I.J.; Ekseth, L.; Kishan, A.U.; Stensvold, A.; Inderberg, E.M.; Lilleby, W. Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer. J. Pers. Med. 2021, 11, 605. https://doi.org/10.3390/jpm11070605

AMA Style

Guldvik IJ, Ekseth L, Kishan AU, Stensvold A, Inderberg EM, Lilleby W. Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer. Journal of Personalized Medicine. 2021; 11(7):605. https://doi.org/10.3390/jpm11070605

Chicago/Turabian Style

Guldvik, Ingrid J., Lina Ekseth, Amar U. Kishan, Andreas Stensvold, Else M. Inderberg, and Wolfgang Lilleby. 2021. "Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer" Journal of Personalized Medicine 11, no. 7: 605. https://doi.org/10.3390/jpm11070605

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop